Scenic Biotech is applying a novel approach to target discovery by harnessing genetic suppressors. Powered by our proprietary technology, Scenic scientists are obtaining a unique and more comprehensive understanding of disease biology. These insights enable us to rapidly identify and validate novel drug targets and then focus on the development of medicines with the greatest potential to impact the lives of patients.
Location: Netherlands, North Holland, Amsterdam
Employees: 11-50
Total raised: $38.39M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Vesalius B... | vesaliusbi... |
| - | Oxford Uni... | innovation... |
| - | Oxford Sci... | oxfordscie... |
| - | Eir Ventur... | eirventure... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.03.2022 | Series A | $31M | - |
| 03.07.2017 | Series A | $7.39M | - |
Mentions in press and media 10
| Date | Title | Description |
| 30.12.2022 | Dutch-based biotech and life sciences startups that raised funding in 2022 | The Netherlands is swiftly rising to the top as a hub for healthcare and life sciences innovation. More and more Dutch startups are engaged in a range of cutting-edge initiatives, such as the creation of digital health tools, the developmen... |
| 31.03.2022 | Meet the Amsterdam-based startups that raised funding in Q1 2022; 31 of them are hiring right now | Dutch startups and scale-ups saw significant growth in investments during the past year. According to a report from DSA (Dutch Startup Association), this trend is likely to continue in 2022, with foreign investors showing a lot of interest ... |
| 11.03.2022 | Scenic Biotech Raises $31M in Series A Financing | Scenic Biotech, an Amsterdam, Netherlands-based provider of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, raised $31M in Series A funding. The round... |
| 10.03.2022 | Roche-partnered Scenic Biotech snags $31M to study 3 rare disease drugs | Roche-partnered Scenic Biotech has scored a $31 million series A financing round and plans to take three drugs into the clinic with a focus on rare genetic diseases. All three programs target genetic modifiers, and the first drug is a small... |
| 10.03.2022 | Amsterdam’s Scenic Biotech raises €28M to specialise in evolution-inspired medicine for rare diseases | Amsterdam-based Scenic Biotech, a developer of genomics and immunotherapy technologies created to unlock genetic suppressors, announced on Thursday that it has raised €28M in its Series A round of funding. The round was co-led by European i... |
| 23.02.2021 | Four exciting companies receive expert mentoring | Four promising healthcare start-ups have proven the viability of their innovations and business plans in a competitive EIT Health Gold Track workshop in February. These start-ups have been selected to progress to the next stage of the prog... |
| 02.02.2021 | PRESS RELEASE: Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman | DGAP-News: Scenic Biotech BV / Key word(s): Personnel Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman 2021-02-02 / 09:30 The issuer is solely responsible for the content of this announcement. =-----------... |
| 02.02.2021 | Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman | DGAP-News: Scenic Biotech BV / Key word(s): Personnel Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman 02.02.2021 / 09:30 The issuer is solely responsible for the content of this announcement. PRESS RELEAS... |
| 03.07.2017 | Scenic Biotech Raises €6.5M in Series A Financing | Scenic Biotech, an Amsterdam, the Netherlands-based therapeutics company, raised €6.5m in Series A financing. The round was co-led by Netherlands-based life sciences investor BioGeneration Ventures (BGV) and INKEF Capital, with the particip... |
| - | Scenic Biotech scores $31M to take aim at genetic modifiers for cancer & rare disease | The role that genetic mutations play in causing disease is understood, and there are plenty of drug discovery efforts focused on molecules that address such abnormalities. But the human genome also contains genes that suppress mutations, an... |